Medical Economics, May 9, 2024: House Small Business Committee hearing focused on when government regulations undermine medical innovation and services but also agreed on the need to ensure safe and effective medical products.
Read More »News That Quotes Us & Our Work
We are often quoted in major newspapers and magazines, and on well-respected TV shows, radio programs, and websites where we share our opinion on issues that matter to you and your health. Stay up to date on health news and our take on it by reading the articles in this section.
FDA Brings Lab Tests Under Its Oversight
MedPage Today, April 29, 2024: FDA issues the final rule for lab-developed tests (LDTs) and we explain that the rule has a giant deadly loophole allowing thousands of diagnostic tests and genetic tests for cancer and other deadly diseases to be sold without evidence they are accurate.
Read More »Feds declare turf, rubber playgrounds “generally safe’
Politico E&E NEWS, April 18, 2024: EPA released its 2024 report on artificial turf, which says it contains dangerous chemicals but that the exposures are “generally safe.’ NCHR’s Dr. Diana Zuckerman asks what does that mean? If it is generally safe that means it isn’t safe for everyone, but EPA doesn’t explain how many will be harmed and doesn’t explain what is known and not known. It’s not credible.
Read More »Americans Are Paying Billions to Take Drugs That Don’t Work
April 15, 2024 By Robert Langreth, Fiona Rutherford and Tanaz Meghjani One ALS drug made $400 million in sales for its maker. It doesn’t work. A cancer treatment brought in $500 million. That one turned out to have no effect on survival. A blood cancer medication made nearly $850 million before being withdrawn for two […]
Read More »10 doctors on FDA panel for Abbott heart device had financial ties to the company. The FDA didn’t disclose the payments.
NBC News and Kaiser Health News, April 6, 2024: NBC News reported the Kaiser Health News investigation showing that 10 doctors who advised FDA about Abbott’s heart device TriClip had financial ties to the company that weren’t disclosed. Their votes almost unanimously supported approval. We explain that FDA conflict of interest rules are too loose.
Read More »